CL2020002177A1 - Indazol-3-carboxamidas sustituidas con 5-heteroarilo y preparación y uso de las mismas - Google Patents
Indazol-3-carboxamidas sustituidas con 5-heteroarilo y preparación y uso de las mismasInfo
- Publication number
- CL2020002177A1 CL2020002177A1 CL2020002177A CL2020002177A CL2020002177A1 CL 2020002177 A1 CL2020002177 A1 CL 2020002177A1 CL 2020002177 A CL2020002177 A CL 2020002177A CL 2020002177 A CL2020002177 A CL 2020002177A CL 2020002177 A1 CL2020002177 A1 CL 2020002177A1
- Authority
- CL
- Chile
- Prior art keywords
- indazole
- heteroaryl
- preparation
- signaling
- wnt pathway
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención divulga compuestos de indazol para tratar diversas enfermedades y patologías. Más particularmente, se refiere al uso de un compuesto de indazol o análogos del mismo, en el tratamiento de trastornos caracterizados por la activación de la señalización de la ruta Wnt, la modulación de eventos celulares mediados por la señalización de la ruta Wnt, así como las afecciones/trastornos/enfermedades neurológicas relacionadas con la sobreexpresión de DYRK1A.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862634656P | 2018-02-23 | 2018-02-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020002177A1 true CL2020002177A1 (es) | 2021-01-08 |
Family
ID=65812386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020002177A CL2020002177A1 (es) | 2018-02-23 | 2020-08-24 | Indazol-3-carboxamidas sustituidas con 5-heteroarilo y preparación y uso de las mismas |
Country Status (18)
Country | Link |
---|---|
US (2) | US10934297B2 (es) |
EP (1) | EP3755696B1 (es) |
JP (1) | JP7369132B2 (es) |
KR (1) | KR20200126393A (es) |
CN (1) | CN112020501A (es) |
AU (1) | AU2019224075A1 (es) |
BR (1) | BR112020017087A2 (es) |
CA (1) | CA3091913A1 (es) |
CL (1) | CL2020002177A1 (es) |
EA (1) | EA202092002A1 (es) |
ES (1) | ES2945558T3 (es) |
IL (1) | IL276814A (es) |
MA (1) | MA51908A (es) |
MX (1) | MX2020008852A (es) |
PE (1) | PE20211447A1 (es) |
PH (1) | PH12020551300A1 (es) |
SG (1) | SG11202008029UA (es) |
WO (1) | WO2019165192A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3091913A1 (en) | 2018-02-23 | 2019-08-29 | Samumed, Llc | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof |
EP3790873B1 (en) * | 2018-05-07 | 2022-04-27 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
WO2020059841A1 (ja) * | 2018-09-21 | 2020-03-26 | 国立大学法人 長崎大学 | プリオン病治療薬 |
WO2021125802A1 (ko) * | 2019-12-16 | 2021-06-24 | 한국화학연구원 | 신규한 인다졸 유도체 및 이의 용도 |
WO2021120890A1 (en) * | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4164559A (en) | 1977-09-21 | 1979-08-14 | Cornell Research Foundation, Inc. | Collagen drug delivery device |
US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
US6440102B1 (en) | 1998-07-23 | 2002-08-27 | Durect Corporation | Fluid transfer and diagnostic system for treating the inner ear |
DE19853299C2 (de) | 1998-11-19 | 2003-04-03 | Thomas Lenarz | Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs |
US6120484A (en) | 1999-02-17 | 2000-09-19 | Silverstein; Herbert | Otological implant for delivery of medicament and method of using same |
US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
US6648873B2 (en) | 2001-09-21 | 2003-11-18 | Durect Corp. | Aural catheter system including anchor balloon and balloon inflation device |
GB0218625D0 (en) * | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
CA2499128C (en) | 2002-09-25 | 2012-07-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
FR2845382A1 (fr) * | 2002-10-02 | 2004-04-09 | Sanofi Synthelabo | Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique |
US7008953B2 (en) | 2003-07-30 | 2006-03-07 | Agouron Pharmaceuticals, Inc. | 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
FR2867778B1 (fr) * | 2004-03-16 | 2006-06-09 | Sanofi Synthelabo | Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme |
MXPA06010852A (es) * | 2004-03-25 | 2007-01-16 | Memory Pharm Corp | Indazoles, benzotiazoles, benzoisotiazoles, bencisoxazoles y preparacion y usos de los mismos. |
CN101001856A (zh) * | 2004-03-25 | 2007-07-18 | 记忆药物公司 | 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑及其制备和用途 |
WO2011050245A1 (en) * | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
BR112014003237A2 (pt) * | 2011-08-12 | 2017-04-25 | Hoffmann La Roche | compostos de indazol, composições e métodos de uso |
EP3473099A1 (en) | 2011-09-14 | 2019-04-24 | Samumed, LLC | Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors |
JP6141331B2 (ja) | 2012-02-21 | 2017-06-07 | アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニAziende Chimiche Riunite Angelini Francesco A.C.R.A.F.Societa Per Azioni | グリコーゲンシンターゼキナーゼ3ベータ阻害剤としての1h−インダゾール−3−カルボキサミド化合物 |
PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
EP3119393A4 (en) | 2014-03-20 | 2018-02-28 | Samumed, LLC | 5-substituted indazole-3-carboxamides and preparation and use thereof |
WO2016040182A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof |
CA3004506A1 (en) | 2015-11-06 | 2017-05-11 | Samumed, Llc | Use of n-(5-(3-(7-(3- fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide in the treatment of osteoarthritis |
CA3026076A1 (en) | 2016-06-01 | 2017-12-07 | Samumed, Llc | Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide |
WO2018075858A1 (en) | 2016-10-21 | 2018-04-26 | Samumed, Llc | Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors |
CA3091913A1 (en) | 2018-02-23 | 2019-08-29 | Samumed, Llc | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof |
-
2019
- 2019-02-22 CA CA3091913A patent/CA3091913A1/en active Pending
- 2019-02-22 JP JP2020544501A patent/JP7369132B2/ja active Active
- 2019-02-22 SG SG11202008029UA patent/SG11202008029UA/en unknown
- 2019-02-22 BR BR112020017087-9A patent/BR112020017087A2/pt not_active IP Right Cessation
- 2019-02-22 US US16/283,366 patent/US10934297B2/en active Active
- 2019-02-22 EP EP19711736.9A patent/EP3755696B1/en active Active
- 2019-02-22 EA EA202092002A patent/EA202092002A1/ru unknown
- 2019-02-22 PE PE2020001271A patent/PE20211447A1/es unknown
- 2019-02-22 ES ES19711736T patent/ES2945558T3/es active Active
- 2019-02-22 CN CN201980027314.1A patent/CN112020501A/zh active Pending
- 2019-02-22 WO PCT/US2019/019129 patent/WO2019165192A1/en unknown
- 2019-02-22 MA MA051908A patent/MA51908A/fr unknown
- 2019-02-22 MX MX2020008852A patent/MX2020008852A/es unknown
- 2019-02-22 KR KR1020207027174A patent/KR20200126393A/ko not_active Application Discontinuation
- 2019-02-22 AU AU2019224075A patent/AU2019224075A1/en not_active Abandoned
-
2020
- 2020-08-19 IL IL276814A patent/IL276814A/en unknown
- 2020-08-20 PH PH12020551300A patent/PH12020551300A1/en unknown
- 2020-08-24 CL CL2020002177A patent/CL2020002177A1/es unknown
- 2020-12-30 US US17/138,098 patent/US11713320B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN112020501A (zh) | 2020-12-01 |
AU2019224075A1 (en) | 2020-09-10 |
WO2019165192A1 (en) | 2019-08-29 |
JP2021516674A (ja) | 2021-07-08 |
PH12020551300A1 (en) | 2021-10-25 |
SG11202008029UA (en) | 2020-09-29 |
ES2945558T3 (es) | 2023-07-04 |
CA3091913A1 (en) | 2019-08-29 |
KR20200126393A (ko) | 2020-11-06 |
US11713320B2 (en) | 2023-08-01 |
EA202092002A1 (ru) | 2021-01-21 |
MX2020008852A (es) | 2020-10-14 |
US20220402921A1 (en) | 2022-12-22 |
PE20211447A1 (es) | 2021-08-05 |
JP7369132B2 (ja) | 2023-10-25 |
US20190263821A1 (en) | 2019-08-29 |
IL276814A (en) | 2020-10-29 |
EP3755696B1 (en) | 2023-04-05 |
EP3755696A1 (en) | 2020-12-30 |
MA51908A (fr) | 2021-06-02 |
US10934297B2 (en) | 2021-03-02 |
BR112020017087A2 (pt) | 2020-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020002177A1 (es) | Indazol-3-carboxamidas sustituidas con 5-heteroarilo y preparación y uso de las mismas | |
CO2019006622A2 (es) | Derivados de pirazol como inhibidores de malt1 | |
CO2018012655A2 (es) | Isoquinolin-3-il-carboxamidas, y preparación y uso de las mismas | |
PH12016501835A1 (en) | 5-substituted indazole -3- carboxamides and preparation and use thereof | |
EA201990187A1 (ru) | Антипролиферационные средства на основе пиримидина | |
CL2018002505A1 (es) | Inhibidores del envejecimiento proteico-proteico wdr5 | |
NI201800124A (es) | 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas | |
CO2020010465A2 (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas | |
PH12018501877A1 (en) | Substituted indole mcl-1 inhibitors | |
CU24564B1 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas | |
CR20180029A (es) | Inhibidores peotídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias | |
CU20180006A7 (es) | Compuestos de indazaol y azaindazol como inhibidores de irak-4 | |
MX2015008860A (es) | Inhibidores de 3-(benzoimidazol-2-il)-indazol de la senda de señalizacion de wnt y usos terapeuticos de los mismos. | |
CO7230336A2 (es) | Inhibidores de indazol de la ruta de señalización de wnt y usos terapeúticos de los mismos | |
CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
MY184882A (en) | Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathyway inhibitors | |
GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
ECSP17038999A (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
PH12019502363A1 (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
EA201792604A1 (ru) | Ингибиторы аутотаксина и их применения | |
CL2017003133A1 (es) | Uso de derivados de bencimidazol para escape ácido nocturno | |
CL2021000292A1 (es) | Benzimidazoles sustituidos como inhibidores de pad4. | |
CR20150496A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
PE20170193A1 (es) | Derivados de 6-alquinil-piridina |